ArticleJournal of cellular and molecular medicine2026
A Network Pharmacology and Experimental Validation Strategy for Hypoglycemic Study of Lonicerae Japonicae Flos on Diabetes.
Article in Journal of cellular and molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
As diabetes has become an important public health issue, Lonicerae Japonicae Flos (LJF) had gradually attracted increasing attention on diabetes. This study aimed to investigate the hypoglycemic ingredients and underlying mechanisms of LJF in diabetes using an integrated strategy of network pharmacology, molecular docking and experimental validation. Network pharmacology screened 73 active ingredients, 65 targets and 20 main signalling pathways. The results of molecular docking, protein-protein interaction and ingredient-target-pathway network indicated that four targets (PPARG, PPARD, MGAM, GAA) and three signalling pathways (PPAR signalling pathway, Starch and sucrose metabolism, Galactose metabolism) played essential roles. Subsequently, animal experiments and in vitro tests were performed to evaluate the anti-diabetic effect, antioxidant capacity and α-amylase inhibitory activity for the LJF extract. Animal studies indicated the LJF alcohol extract could significantly decrease blood glucose level and mitigate the weight loss compared to the model group (p < 0.05), respectively. Furthermore, both in vitro and in vivo tests confirmed that the LJF alcohol extract exhibited strong antioxidant capacity (p < 0.05 for MDA and SOD) and α-amylase inhibitory activity (maximum efficacy: 66.6% ± 4.6%). This strategy provided a promising approach to further elucidate the active ingredients and underlying mechanisms of LJF and other herbs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.